基本信息
浏览量:1
职业迁徙
个人简介
Hollis Showalter joined the University of Michigan in 2006 after more than 25 years of drug discovery and development experience within the pharmaceutical industry. He has broad experience in synthetic medicinal chemistry and has contributed to a number of campaigns resulting in agents proceeding to clinical trials. One of these, Nipent™, is marketed for the treatment of hairy cell leukemia. He was the founding Director of the University of Michigan Vahlteich Medicinal Chemistry Core (UMVMCC.org), which works with collaborators in hit-to-lead campaigns to advance their drug discovery efforts, contribute synthetic and medicinal chemistry strategies to grant proposals, and develop biological probes or potential therapeutic agents for biological investigation. He also provides expertise on intellectual property protection. He has published 173 peer reviewed manuscripts/reviews/book chapters, and 161 meeting abstracts. He holds 47 issued or applied for patents.
研究兴趣
论文共 107 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Xuwen Liu,Michael W Wilson, Kun Liu,Pil Lee,Larisa Yeomans, Susan E Hagen,Cheng-Mao Lin,Bo Wen,Duxin Sun,Andrew D White,Hollis D Showalter,David A Antonetti
Bioorganic & medicinal chemistryno. 11 (2020): 115480-115480
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALSno. 5 (2019): 202-208
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn